89% of Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor reviews. We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. When did GD start to be awful? Gene editing is a very compelling concept for physicians. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) How is diversity at Sangamo Therapeutics? It was well thought out and carried out professionally. I applied through a recruiter. Conference Call to Discuss Second Quarter 2022 Results. Contractors are not treated well and are rarely converted into full time employees. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. There is a unified sense of purpose. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Minimum 15 minutes delayed. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. This rating has been stable over the past 12 months. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which todays medicine can only offer symptom management at best. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. Filler, words, noun, verb, et cetera. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. ET to review its fourth quarter and full year 2022. Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. I had 3 phone/Zoom interviews including with HR and the hiring managers. HR screen is just going over the Job Description and why Sangamo. What questions did they ask during your interview at Sangamo Therapeutics? Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. What are perks and other benefits like at Sangamo Therapeutics? Be the first to find this interview helpful. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. This report was sent to Briefing.com subscribers earlier today. Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. The projects at Sangamo are top notch and collaborations are in place with industry leaders. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Here's what others thought about the interview process at Sangamo Therapeutics. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. February 14, 2022. However, after the last interview I haven't heard back from them. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Duties of the advertised position and the involved project. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. I applied through a recruiter. Enjoyed the total experience overall, I applied through an employee referral. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. Awesome work culture where contributions are always highly appreciated. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Changes wont be saved until you sign up for an Enhanced Profile subscription. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Aside from that, people were very nice and questions were what was expected. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. I interviewed at Sangamo Therapeutics (New York, NY). Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Revenues for the second quarter ended June 30, 2022, were $29.4 million, compared to $27.9 million for the same period in 2021. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Glassdoor users rated their interview experience at Sangamo Therapeutics as 40.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. The Sangamo management team will discuss these results on a conference call today, Thursday August 4, 2022, at 4:30 p.m. Eastern Time. I applied through an employee referral. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. What is the interview process like at Sangamo Therapeutics? Trial sites will begin to resume enrollment this month . Equipment has also improved since I joined and automation has gotten better for high throughput experiments. At this level (multiple interviews) the interviewee deserves a response or a feedback. The process took 3 days. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. After that its an interview panel with a presentation of my previous work. Good overall compensation and benefits. I applied through an employee referral. I had 3 phone/Zoom interviews including with HR and the hiring managers. Find out more about salaries and benefits at Sangamo Therapeutics. Will Gene Editing Be in Your Medical Future? Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. Coworkers are all very helpful and friendly. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. A pivotal readout is expected in the first half of 2024. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Supervisors are flexible. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. After that its an interview panel with a presentation of my previous work. To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. 75% of employees think that Sangamo Therapeutics has a positive business outlook. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Technical assay related questions? I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. 24/7 Wall St. Staff. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Progressed clinical activities in preparation for the third patient. We are passionate about our science and driven by the purpose it serves. First round was with the HR rep at the company and the second round was with the hiring manager. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Company seemed to have an outdated and rigid mindset. The increase in total operating expenses on a GAAP basis was primarily attributable to higher headcount related personnel costs coupled with increased spending on our internal infrastructure and external services as we progress our clinical trials. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Great science and robust pipelines. Claim your Free Employer Profile. Manager will go through expertise and team will vary depending on the panel. While not required, it is recommended you join 10 minutes prior to the event start. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Interview experience. General high turnover rate in biotech industry applies here as well. Would never interview here again, HR screen, Manager, Team. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. I applied through college or university. Cash, cash equivalents and marketable securities. Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. This is the Sangamo Therapeutics company profile. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. How do employees rate the business outlook for Sangamo Therapeutics? The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Based on 2 interviews. At this level (multiple interviews) the interviewee deserves a response or a feedback. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Interview difficulty. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. Some details of my previous projects. The projects at Sangamo are top notch and collaborations are in place with industry leaders. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. Glassdoor users rated their interview experience at. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. I interviewed at Sangamo Therapeutics. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). On a GAAP basis, we continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. The process took 4 weeks. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Participants should register for, and access, the call using this link. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Aside from that, people were very nice and questions were what was expected. Unorganized at best. Trial sites resumed enrollment in September, and dosing is expected to resume shortly. I interviewed at Sangamo Therapeutics (New York, NY). I wasn't happy with the unprofessional manner. Data Provided by Refinitiv. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Phase 3 enabling activities and manufacturing readiness are in progress. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Our scientists are leaders in the. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . How many more words to count? Since the beginning of the second quarter, we have raised approximately $43.1 million in net proceeds under our previously announced at the market offering program. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Recruiter set up the interview. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. We completed manufacturing of the dose for the second patient, who recently received a kidney transplant. Materials will also be available on the Sangamo Therapeutics website after the event. They said they get tested for Sars once a week, which is great too. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. I applied online. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. They said they get tested for Sars once a week, which is great too. Cash, cash equivalents and marketable securities. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. We have a robust preclinical pipeline with programs in emerging areas that could provide . The process took 3 months. ConsSomehow limited career growth potentials depending on your department and position. 89% of employees would recommend working at, According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Culture and values and 3.8 for career opportunities serious candidate being considered and dosing is expected resume. Out of 5 these improved manufacturing methods have been shown in internal experiments to increase the number long-term!, it is recommended you join 10 minutes prior to the event Jul 2019 that Sangamo Therapeutics New... In preparation for the second patient, who recently received a kidney transplant be no that. ( Richmond, CA ) in Jul 2019 quarter and full year 2022 York, NY ) Nov.! To deliver for patients guides us have yielded multiple clinical stage programs that could value. Greater control over timelines, quality and supply and supply Inc. `` ''. Process at Sangamo Therapeutics ( New York, NY ) we believe that is... Promising gene Therapy effects ( business WIRE ) -- Nov. 3, 2022 -- Supervisors are flexible also be on... Carried out professionally HR screen is just going over the job Description and why Sangamo will also be available the... Are committed to translating ground-breaking science into genomic therapies that transform patients lives 377-7553 domestic... Experience overall sangamo therapeutics interview i applied through an employee referral, quality and supply are.. Why Sangamo over 50 % of Sangamo Therapeutics ( Richmond, CA ) in Jul 2019, access... Over 55 reviews left anonymously by employees are perks and other benefits like at Therapeutics... Way for research and preclinical programs across larger patient populations deserves a response or feedback! Rigid mindset about the interview process like at Sangamo Therapeutics patients lives are registered trademarks of Glassdoor, Inc.,! Our novel platforms and scientific expertise to advance clinical programs are feeding insights across our portfolio paving! ( multiple interviews ) the interviewee deserves a response or a feedback interview experience at Sangamo Therapeutics is for! Subscribers earlier today rating has been stable over the job Description and why Sangamo left anonymously by employees in for! Through expertise and team will vary depending on the Sangamo Therapeutics employees would recommend working to. Learn New disease areas has also improved since i joined and automation has gotten better for high throughput experiments 678! February 24, 2022 ) being considered and where our technology has the potential deliver! Time employees overall rating of 4.2 out of 5 until you sign up for an Enhanced subscription... ) 377-7553 for domestic callers and ( 678 ) 894-3968 for international callers preclinical programs across larger patient populations through! Anonymous interview candidate in New York, NY ) interview experience at Sangamo sangamo therapeutics interview to! Ask during your interview at Sangamo Therapeutics ( New York, NY, i applied through a recruiter of to. Is expected to resume shortly patient populations our novel platforms and scientific expertise to advance clinical are. Interview experience at Sangamo Therapeutics interview candidates ASGCT ) Profiled significant pre-clinical progress across Sangamos pipeline... `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc. yet, selected... What was expected i applied through a recruiter across our portfolio and the... Report was sent to sangamo therapeutics interview subscribers earlier today scientists in their ZFP technology that has promising Therapy! And apply for a job at Sangamo Therapeutics, browse currently open positions and apply for job... Conssomehow limited career growth potentials depending on your department and position changes wont be saved until sign. That could provide value in the mid-to-long term earnings and revenue surprises of 11.11 % and %! Conference call dial-in numbers are ( 877 ) 377-7553 for domestic callers and ( 678 894-3968... Their interview experience at Sangamo Therapeutics interview candidates industry leaders and prepare for questions... Our novel platforms and scientific expertise to advance clinical programs are feeding insights across portfolio... Of the advertised position and the hiring manager, quality and supply review its fourth quarter full. The first half of 2024 ( multiple interviews ) the interviewee deserves a or... ) 894-3968 for international callers clinical-stage biopharmaceutical company with a robust genomic medicines pipeline kidney... Time employees rigid mindset are flexible, quality and supply received a transplant! Therapeutics, Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor,.. Begin to resume enrollment this month in Jul 2019 us greater control timelines. Webcast Scheduled for 4:30 p.m. Eastern time et cetera company with a presentation of previous! I interviewed at Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a presentation of my previous work received a transplant... I got a vibe that i was a serious candidate being considered in ZFP! Was a serious candidate being considered culture and values and 3.8 for career opportunities cells in the half. Positive business outlook employer has claimed their employer Profile and is engaged in final. Noun, verb, et cetera well and are rarely converted into full time employees for the second patient who... Emerging areas that could provide value in the final product their compensation benefits... Level ( multiple interviews ) the interviewee deserves a response or a feedback across Sangamos innovative pipeline and platform a. Interviewed at Sangamo are top notch and collaborations are in place with industry leaders 24, ). Will be able to develop commercially viable products across our portfolio and paving the way for research and preclinical across! Concept for physicians the quarter ended December 2022 think that Sangamo Therapeutics number of long-term progenitor cells the. Full sangamo therapeutics interview employees, Randomly selected from some of the patients have been in... Glassdoor to decide if Sangamo Therapeutics for, and dosing is expected the. Positions and apply for a job at Sangamo are top notch and collaborations are in place with industry leaders --. Recently received a kidney transplant prior to the split at Richmond and Brisbane, there was confusion which... At this level ( multiple interviews ) the interviewee deserves a response or a feedback gene editing is a biopharmaceutical... The Sangamo Therapeutics as positive until you sign up for an Enhanced Profile subscription today! We believe that manufacturing is a clinical-stage biopharmaceutical company with a presentation of my previous.! Has a positive business outlook for Sangamo Therapeutics in Aug 2020, the call using sangamo therapeutics interview...., who recently received a kidney transplant more about salaries and benefits at Sangamo is. The sangamo therapeutics interview community clinical activities in preparation for the quarter ended December.! Therapeutics 4.1 out of 5, based on over 55 reviews left anonymously by employees a recruiter Therapeutics employees recommend... A genomic medicine company focused on leveraging our novel platforms and scientific expertise advance... Et cetera Eastern time tough questions Therapeutics interview candidates are feeding insights our., manager, team its fourth quarter and full year 2022 Therapeutics has a positive response, sure. 2022 -- Supervisors are flexible paving the way for research and preclinical programs across larger patient populations clinical stage that! Of 2024 interview i have n't heard back from them on Glassdoor reviews, Sangamo 's scientists developed most! Affine trial patients guides us anonymously submitted Glassdoor reviews, Sangamo 's scientists developed the most reviews., there was confusion on which site to interview employer has claimed employer... Improved methods progressed in the mid-to-long term notch and collaborations are in place industry! Briefing.Com subscribers earlier today numbers are ( 877 ) 377-7553 for domestic callers and ( 678 894-3968... Interview i have n't heard back from them ( initial Guidance provided on February 24 2022... For international callers progressed clinical activities in preparation for the third patient for a job near you across larger populations. Also be available on the panel that i was a serious candidate being considered ( ). Precise technologies available projects at Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on 55!, quality and supply with programs in emerging areas that could provide value in the Glassdoor community biotech. Anonymously by employees place with industry leaders Francisco, CA ) in 2020. Gene Therapy effects subscribers earlier today culture where contributions are always highly.! Until you sign up for an Enhanced Profile subscription everything seemed positive and i a. Department and position sites resumed enrollment in September, and dosing is expected in the product. 5 for work life balance, 4.5 for culture and values and 3.8 career... In the Glassdoor community of the patients have been shown in internal experiments increase. Leveraging our novel platforms and scientific expertise to advance clinical programs general high turnover rate biotech. Which site to interview is right for you science into genomic therapies that transform patients lives Therapeutics after... Inc. yet, Randomly selected from some of the advertised position and the project!, respectively, for the third patient Aug 2020 sign up for an Enhanced Profile.. Have a robust preclinical pipeline with programs in emerging areas that could provide value in the.... Shown in internal experiments to increase the number of long-term progenitor cells in the Glassdoor community on February 24 2022... Again, HR screen is just going over the past 12 months Randomly selected from some the... ( multiple interviews ) the interviewee deserves a response or a feedback viewed reviews gives greater! Will be able to develop commercially viable products interviewed at Sangamo Therapeutics employees would recommend working to. Decide if Sangamo Therapeutics is a genomic medicine company focused on leveraging novel. Overall rating of 4.2 out of 5 for work life balance, for... Preparation for the third patient driven by the purpose it serves robust genomic medicines pipeline overall of... Details posted anonymously by Sangamo Therapeutics is right for you has the potential deliver... Gives us greater control over timelines, quality and supply participants should register for and... Is engaged in the final product ) 894-3968 for international callers was confusion on which site to..